Edan Instruments Inc

Edan Instruments Inc maintains a strong liquidity position, with a current ratio of 4.67, indicating the company can easily cover its short-term liabilities with its current assets. The company's liquidity_fpt score is high, supported by a free cash flow of 157.5 million CNY and a low debt-to-equity ratio of 0.02, suggesting minimal leverage risk. However, the risk assessment notes that net cash is negative after subtracting total debt, which could signal potential liquidity constraints if cash flow from operations declines.

In terms of profitability, Edan Instruments Inc generates a return on equity (ROE) of 13.94% and a return on assets (ROA) of 11.56%, both of which are strong indicators of efficient capital use and asset management. These metrics are well above the industry median for the Advanced Medical Equipment & Technology sector, where ROE and ROA typically range between 8% and 10%. The company's operating margin of 15.6% and net margin of 15.3% also reflect solid profitability, with gross profit of 1.16 billion CNY on total revenue of 1.999 billion CNY.

Geographically, Edan Instruments Inc is primarily focused on the Chinese market, with a significant portion of its revenue derived from domestic operations. The company's revenue concentration in a single region exposes it to regulatory and economic risks specific to China, including potential changes in healthcare policy and reimbursement rates. There is no disclosed information on international revenue segments, suggesting limited geographic diversification.

The company's growth trajectory is positive, with a revenue of 1.999 billion CNY in the latest reporting period. While no specific outlook for the next fiscal year is provided, the company's strong operating cash flow of 352.9 million CNY and capital expenditure of -84.7 million CNY suggest a focus on maintaining and optimizing existing operations rather than aggressive expansion. The negative capital expenditure indicates that the company is generating more cash than it is investing in new assets, which could be a sign of maturity in its business cycle.

Risk factors for Edan Instruments Inc include medium liquidity risk and low dilution risk. The company's liquidity risk is moderate due to its strong cash flow and low debt levels, but the negative net cash position after debt is a cautionary signal. Dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares, and there are no indications of recent or planned share issuances. The risk assessment also notes that the company has not disclosed any material dilution sources in its recent filings.

Recent events and disclosures for Edan Instruments Inc include a strong analyst recommendation with a mean rating of 1.00 (strong buy) and one strong-buy count, indicating positive sentiment among analysts. The company's latest actual EPS of 0.53 CNY is slightly below the mean EPS estimate of 0.61 CNY, suggesting potential upside in earnings performance. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes.